DreaMed Diabetes technology to be used in Medtronic insulin pump

Your Health Matters

Israel-based DreaMed Diabetes said on Monday it had licensed its artificial pancreas technology for integration into insulin pumps made by Medtronic. DreaMed will receive undisclosed royalties from future sales of each device using its technology. Medtronic will be responsible for the development and marketing of the pumps. The U.S. medical device maker has also invested $2 million in DreaMed.  DreaMed’s GlucoSitter, which is based on the MD-Logic Artificial Pancreas algorithm, is an automated system for controlling glucose levels.
Go to Source

facebookShare on Facebook
TwitterTweet
FollowFollow us
PinterestSave